oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Our Topics
Recent Posts
Contact
oncgnostics GmbH
BioInstrumentezentrum Jena
Winzerlaer Str. 2
07745 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
EURONEXT Chooses Oncgnostics
UncategorizedOncgnostics GmbH is greatly honoured to have been selected by EURONEXT for the TechShare programme. We will be participating in top-class workshops and coaching sessions for half a year. High-quality Coaching for Start-ups As one of eleven German start-ups in the medical and biotech sectors, we will have the opportunity to broaden our horizons over […]
Expert Lecture in Spain
UncategorizedOn 12 June, the conference ‘XIII Jornada de Formación en Patología del Tracto Genital inferior y Colposcopia‘ was held in Madrid. Oncgnostics’ managing director Dr Alfred Hansel was one of the speakers at the training event for gynaecologists. Experts Exchange Knowledge At the conference, experts updated their knowledge on HPV-related cancers in women’s genital tract. […]
Surprise at Investor Days Thüringen
UncategorizedOn 18 June oncgnostics managing director, Dr Alfred Hansel, visited Investor Days Thüringen in Erfurt, and was pleased to receive the ‘bm|t sustainable business award’. Thuringia’s Sector Network Meeting As a large sector network meeting, Investor Days bring together the different parties involved: Young companies, investors, decision makers and representatives from economy, science and politics. […]
Congress on Head and Neck Oncology
UncategorizedThe International Congress on Innovative Approaches in Head and Neck Oncology (ICHNO) took place, for the seventh time, in Barcelona from 14 to 16 March. Anna-Bawany Hums participated in the interdisciplinary exchange of experts on behalf of oncgnostics GmbH. Specialists from all over the World Among the approximately 600 international participants, there were clinicians from […]
Delegation Trip to India
UncategorizedFrom the 9 to the 16 In February, our managing director Dr Martina Schmitz travelled to India as a participant of the delegation trip ‘Thuringia goes India’. There she got an impression of the Indian market and made first contacts. The trip took place under the direction of Wolfgang Tiefensee, Thuringia’s Minister for Economic Affairs, […]
Early detection test GynTect® now available for Roche Diagnostics QPCR system
Press ReleasesJena, 20. February, 2019 – The test for early detection of cervical cancer GynTect® may now also be performed on the cobas Z480 analyzer, a widely used quantitative PCR (QPCR) system from Roche Diagnostics. This is now possible through an extension of the GynTect® CE IVD mark (CE mark for in vitro diagnostics). The biotech […]
Oncgnostics GmbH Presents New Clinical Data on GynTect® Precision Diagnostics at EUROGIN 2018
Press Releases, UncategorizedOncgnostics will discuss new clinical data with gynaecological key opinion leaders at EUROGIN 2018 SAN FRANCISCO, CA, USA, November 29, 2018 — Oncgnostics GmbH presents new clinical data on GynTect® Precision Diagnostics for triage of unclear cervical cancer screening tests. Oncgnostics GmbH, a Jena/Germany based company, has developed GynTect® for precision detection of cervical cancer. […]
Cervical Cancer Screening: oncgnostics Closes further Investment Round
Press ReleasesJena, October 17, 2018 – The Thuringian molecular diagnostics company oncgnostics, which quickly and successfully closed a 750,000 Euros crowd-investing round on Seedmatch early in 2018, now announces the closing of another similarly sized round. oncgnostics has developed the cervical cancer diagnostics test GynTect®, and a private investor circle now invests together with the current […]
Oncgnostics GmbH retains Biotech Alliances International Inc. to support global partnering and distribution strategy.
Press Releases2018-10-02 San Francisco/Jena, Germany: Biotech Alliances International Inc., a Silicon Valley-based healthcare-focused investment bank, announced today that it will serve as the lead investment banker to Oncgnostics globalisation and partnering strategy. Early detection of cervical cancer is critical for patient’s health and survival. Current diagnostic methods are inefficient and fail to detect 50% of the […]
Cervical Cancer and Uterine (Body) Cancer – What is the Difference?
UncategorizedAlthough cervical cancer and uterine (body) cancer develop only a few centimetres apart, there are big differences in the cause of the disease. Therefore, the fields of research and treatment are also fundamentally different. This article will explain the differences, for a better understanding. First, anatomy, in order to be able to better classify where […]